[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100363604":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":39,"collaborators":10,"id":41,"slug":10,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":42,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":51,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},{"fullName":5,"class":6},"Kyowa Kirin Co., Ltd.","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Transplant Arm",null,"Patients with CTCL or ATLL who received mogamulizumab within one year prior or up to 18 months after alloHCT",{"label":13,"type":10,"description":14,"interventionNames":10},"Control Arm","Patients who have undergone alloHCT without exposure to mogamulizumab pre- or post-alloHCT",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Linda J Burns, MD","CONTACT","414-805-0714","lburns@mcw.edu",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Jatin Jadwani, BDS, MSc Clinical Research","+49 15114861167","jatin.jadwani@kyowakirin.com",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"CIBMTR","RECRUITING","Milwaukee","Wisconsin","53226","United States",{"type":34,"coordinates":35},"Point",[36,37],-87.90647,43.0389,{"lat":37,"lon":36},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100363604",false,"NCT04014374","Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab","Inclusion Criteria:\n\n* Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)\n* Adults ≥18 years of age with either CTCL or ATLL;\n* AlloHCT performed from January 2012 onward.\n\nExclusion Criteria:\n\n• Patients without consent for research.","ALL","18 Years",{"count":49,"type":50},150,"ESTIMATED","2 Years","OBSERVATIONAL","This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.",[55,56,57],"Leukemia\u002FLymphoma","Cutaneous T Cell Lymphoma","ATLL","2024-07-23",{"date":60,"type":61},"2024-07-24","ACTUAL",{"date":63,"type":61},"2019-09-10",{"date":65,"type":50},"2030-02",{"name":67,"class":6},"Kyowa Kirin, Inc.",1]